KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Restructuring Costs (2022 - 2025)

Pacira BioSciences has reported Restructuring Costs over the past 4 years, most recently at $851000.0 for Q4 2025.

  • Quarterly results put Restructuring Costs at $851000.0 for Q4 2025, down 82.38% from a year ago — trailing twelve months through Dec 2025 was $14.5 million (up 87.78% YoY), and the annual figure for FY2025 was $14.1 million, up 83.23%.
  • Restructuring Costs for Q4 2025 was $851000.0 at Pacira BioSciences, down from $6.8 million in the prior quarter.
  • Over the last five years, Restructuring Costs for PCRX hit a ceiling of $10.9 million in Q4 2022 and a floor of -$1.8 million in Q3 2024.
  • Median Restructuring Costs over the past 4 years was $1.4 million (2023), compared with a mean of $2.7 million.
  • Biggest five-year swings in Restructuring Costs: plummeted 1120.81% in 2024 and later soared 484.54% in 2025.
  • Pacira BioSciences' Restructuring Costs stood at $10.9 million in 2022, then crashed by 113.32% to -$1.5 million in 2023, then surged by 432.64% to $4.8 million in 2024, then crashed by 82.38% to $851000.0 in 2025.
  • The last three reported values for Restructuring Costs were $851000.0 (Q4 2025), $6.8 million (Q3 2025), and $634000.0 (Q2 2025) per Business Quant data.